Belinda Childs
Clinical Nurse Specialist · Wichita, KSNPI 1609969757
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $5,496 of the $6,861 with a category attached, or 80.1%. It is spread thinly across 24 manufacturers, the largest accounting for just 23.9% — the pattern of someone who eats at a lot of different presentations.
Across 357 payments — averaging $19.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi-aventis U.S. LLC$2K
- Lilly USA, LLC$907
- Novo Nordisk$759
- Insulet Corporation$585
- Dexcom, Inc.$580
- Abbott$520
- plus $2K from 18 others
Across 1 payment — averaging $1400.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Abbott$1K
What the payments were for
- Consulting fees$2103%
- Speaking & faculty fees$1,14417%
- Food & beverage$5,49680%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi-aventis U.S. LLC | 20 | $1,642 |
| Lilly USA, LLC | 50 | $907 |
| Novo Nordisk | 75 | $759 |
| Insulet Corporation | 60 | $585 |
| Dexcom, Inc. | 48 | $580 |
| Abbott | 40 | $520 |
| Bayer | 11 | $382 |
| Medtronic | 6 | $222 |
| Embecta Corp. | 2 | $219 |
| Boehringer Ingelheim | 11 | $208 |
| AstraZeneca | 6 | $190 |
| Xeris Pharmaceuticals, Inc. | 9 | $152 |
| Cequr Corporation | 1 | $108 |
| Nevro Corp. | 2 | $92 |
| Corcept Therapeutics | 4 | $82 |
| Amarin Pharma, Inc. | 3 | $48 |
| AbbVie | 2 | $34 |
| Amgen | 1 | $27 |
| Sequel Med Tech, LLC | 1 | $22 |
| Zealand Pharma US, Inc. | 1 | $20 |
| Tandem Diabetes Care, Inc. | 1 | $18 |
| BD | 1 | $16 |
| Ascensia Diabetes Care US Inc. | 1 | $16 |
| Merck | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few clinical nurse specialist providers in Kansasto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 261 | $307,222 |
| MounjaroTirzepatide | 153 | $190,068 |
| TrulicityDulaglutide | 119 | $130,382 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 104 | $126,670 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 153 | $101,581 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 102 | $92,537 |
| Tresiba Flextouch U-200Insulin Degludec | 56 | $91,021 |
| FarxigaDapagliflozin Propanediol | 122 | $88,870 |
| Tresiba Flextouch U-100Insulin Degludec | 155 | $88,708 |
| Novolog FlexpenInsulin Aspart | 295 | $79,100 |
| JardianceEmpagliflozin | 91 | $75,903 |
| Humalog Kwikpen U-100Insulin Lispro | 150 | $42,429 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 46 | $36,292 |
| Lyumjev Kwikpen U-100Insulin Lispro-Aabc | 27 | $20,250 |
| Xultophy 100-3.6Insulin Degludec/Liraglutide | 12 | $19,164 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Xultophy 100-3.6, Novolog | $759 | $343,735340 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog, Insulin Lispro | $907 | $332,720337 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus | $1,642 | $99,083166 claims |
| AstraZenecaFarxiga | $190 | $88,870122 claims |
| Boehringer IngelheimJardiance | $208 | $75,90391 claims |
| MerckJanuvia | $13 | $18,92325 claims |
| AbbVieSynthroid | $34 | $2,01337 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few clinical nurse specialist providers in Kansason file to place this against a meaningful peer group, so we don't.
Other clinical nurse specialist in Wichita
- Emilie HaganWichita$733
- Melissa WhitesideWichita$619
- Jean DukichWichita$18
- Nancy RichardsKansas City$9K
- Kacie HeidShawnee Mission$2K
- Barbara LeeKansas City$959
- Tamara SmithAndover$959
- Whitney McMillenKansas City$722
- Maria FoxOverland Park$396
- Katelyn SappWestwood$276
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.